I-SPY COVID News Coverage

January 4, 2023

Quantum Leap Announce Termination of Cyproheptadine Treatment Arm Patients in the I-SPY COVID Trial

September 15, 2022

I-SPY COVID, with Omeros Corporation, Reports Assessment of Narsoplimab for Treatment With COVID-19

August 8, 2022

Quantum Leap Announces Termination of the Cyclosporine Treatment Arm for Critical COVID-19 Patients

March 31, 2022

I-SPY COVID Trial by Quantum Leap Suggests No Benefit with Nebulized ZYESAMI for COVID-19 Patients

January 10, 2022

No Benefit by Addition of Pulmozyme to Treat Critical Patients With COVID-19 in I-SPY COVID Trial

December 3, 2021

I-SPY COVID Trial Shows No Clinical Benefit from Added IC14 to Treatment of Patients with COVID-19

September 2, 2021

Quantum Leap Concludes Famotidine Celebrex Does Not Reduce Recovery Time in the I-SPY COVID Trial

April 28, 2021

Quantum Leap Concludes Cenicriviroc Unlikely to Reduce Recovery Time in I-SPY COVID Trial

April 15, 2021

I-SPY COVID Trial by Quantum Leap Suggests Icatibant not Likely to Impact Critical COVID-19 Patients

March 12, 2021

Quantum Leap Concludes Apremilast Unlikely to Reduce Recovery or Mortality Time in I-SPY COVID Trial

March 5, 2021

Quantum Leap Discontinues Testing of Aerpio's Razuprotafib in I-SPY COVID Trial

December 15, 2020

HHS, DOD engage Quantum Leap Healthcare Collaborative

September 19, 2020

This theory might explain “Covid toes” and other mysteries of the disease

August 27, 2020

Oncologists Train ARDS Docs for 'Inspirational' COVID-19 Trial

July 30, 2020

The COVID R&D Alliance and Quantum Leap Healthcare Enroll First Patients in I-SPY COVID Trials

May 27, 2020

Quantum Leap Healthcare Selects Aerpio's Razuprotafib for I-SPY COVID Trial for ARDS patients

April 28, 2020

Dr. Laura Esserman on How to think about your cancer care in the time of COVID-19

April 28, 2020

Quantum Leap Healthcare Collaborative launches the I-SPY COVID study for ARD's ICU patients

This link leads to the machine-readable files that are made available in response to the federal Transparency in Coverage Rule and includes negotiated service rates and out-of-network allowed amounts between health plans and healthcare providers. The machine readable files are formatted to allow researchers, regulators, and application developers to more easily access and analyze data.